GIP: The 'Other' Incretin Hormone Is Now Revealing Its Hidden Anti-Inflammatory Powers
GIP (glucose-dependent insulinotropic polypeptide) has context-dependent pro- and anti-inflammatory effects, and understanding its immunomodulatory role is crucial as GIP/GLP-1 dual agonists like tirzepatide gain widespread use.
Quick Facts
What This Study Found
GIP's effects on inflammation are context-dependent and influenced by tissue-specific receptor expression and metabolic status. Experimental models show both pro-inflammatory and anti-inflammatory effects depending on the setting. GIP/GLP-1 dual agonists have demonstrated improved glycometabolic and inflammatory outcomes in clinical use, but the individual contributions of each pathway remain unclear.
The GIP receptor (GIPR) is expressed on immune cells and tissues beyond the pancreas, providing a biological basis for immunomodulatory effects. The review highlights GIPR as a promising but understudied target in the emerging field of immunometabolism.
Key Numbers
How They Did This
Comprehensive narrative review of the scientific literature from GIP's discovery to present, examining preclinical and clinical evidence linking GIP to inflammatory processes. Pharmacological approaches targeting the GIP receptor — including GIP-based multi-target (dual and triple agonist) therapies — are discussed in relation to inflammatory outcomes.
Why This Research Matters
Chronic low-grade inflammation is now recognized as a key driver of type 2 diabetes, obesity, cardiovascular disease, and metabolic syndrome. As millions of patients take tirzepatide and newer dual/triple agonists, understanding GIP's specific contribution to anti-inflammatory effects is essential for optimizing these drugs, identifying which patients benefit most, and developing next-generation therapies that target inflammation more precisely.
The Bigger Picture
GIP has long been the neglected incretin — overshadowed by GLP-1 in both research attention and drug development. Tirzepatide's stunning clinical success has forced a reassessment: GIP may contribute far more to metabolic improvement than previously thought. This review positions GIP's anti-inflammatory effects as a potentially major yet underexplored component of dual agonist efficacy, with implications for drug design, patient selection, and our understanding of gut-immune communication.
What This Study Doesn't Tell Us
Clinical data on GIP's anti-inflammatory effects are still limited. Most evidence comes from preclinical models, which may not translate directly to humans. The context-dependent nature of GIP's effects (sometimes pro-inflammatory, sometimes anti-inflammatory) makes it difficult to predict clinical outcomes. The review acknowledges that disentangling GIP from GLP-1 contributions in dual agonist therapies remains an unsolved challenge.
Questions This Raises
- ?Does GIP receptor activation contribute to the cardiovascular benefits of tirzepatide, or is this primarily a GLP-1-mediated effect?
- ?Could selective GIP receptor agonists be developed as standalone anti-inflammatory therapies for metabolic diseases?
- ?What tissue-specific factors determine whether GIP promotes or suppresses inflammation in a given context?
Trust & Context
- Key Stat:
- Context-dependent inflammation effects GIP can be both pro- and anti-inflammatory depending on tissue type and metabolic state — a complexity that must be resolved to optimize GIP-based therapies
- Evidence Grade:
- This is a narrative review of preclinical and limited clinical literature. While it provides a comprehensive overview of an emerging field, much of the evidence for GIP's immunomodulatory effects comes from experimental models rather than clinical studies.
- Study Age:
- Published in 2026, this is a very current review reflecting the intense research interest in GIP biology driven by tirzepatide's clinical success and the development of next-generation multi-agonist therapies.
- Original Title:
- The role of the incretin GIP in inflammation.
- Published In:
- Journal of endocrinological investigation, 49(2), 255-266 (2026)
- Authors:
- Rossi, Giada, Bucciarelli, Loredana(2), Cimino, Vincenzo(2), Fiorina, Paolo
- Database ID:
- RPEP-16016
Evidence Hierarchy
Frequently Asked Questions
What is GIP and how is it related to drugs like tirzepatide?
GIP (glucose-dependent insulinotropic polypeptide) is a hormone released by your gut after eating. Along with GLP-1, it's one of the two main 'incretin' hormones that help regulate blood sugar. Tirzepatide activates both GIP and GLP-1 receptors, which appears to make it more effective than drugs targeting GLP-1 alone. This review explores an additional benefit of GIP activation: potential anti-inflammatory effects.
Why can GIP be both pro- and anti-inflammatory?
GIP receptors are found on many different types of immune cells and tissues, and the effect of activating them depends on which cells are involved and what the metabolic environment looks like. In some contexts (like adipose tissue in obesity), GIP may promote inflammation, while in others (like certain immune cells), it may suppress it. This complexity is why researchers are working to understand the specific conditions under which GIP helps or hinders inflammation.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-16016APA
Rossi, Giada; Bucciarelli, Loredana; Cimino, Vincenzo; Fiorina, Paolo. (2026). The role of the incretin GIP in inflammation.. Journal of endocrinological investigation, 49(2), 255-266. https://doi.org/10.1007/s40618-025-02719-w
MLA
Rossi, Giada, et al. "The role of the incretin GIP in inflammation.." Journal of endocrinological investigation, 2026. https://doi.org/10.1007/s40618-025-02719-w
RethinkPeptides
RethinkPeptides Research Database. "The role of the incretin GIP in inflammation." RPEP-16016. Retrieved from https://rethinkpeptides.com/research/rossi-2026-the-role-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.